Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Submits IND for HCV Drug

Premium

Benitec Biopharma announced this week that it has submitted an investigational new drug application to begin phase I/IIa testing of its expressed RNAi-based hepatitis C treatment TT-034.

TT-034 expresses shRNAs targeting three portions of the HCV genome. It was originally developed by Benitec, but financial problems led the company to license the agent to startup Tacere Therapeutics in 2006.

Benitec acquired Tacere last year, reacquiring the HCV program. It expects to begin human testing of TT-034 early next year.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.